India's domestic pharmaceutical industry will be subject to heightened scrutiny in light of ongoing quality control issues among domestic manufacturers, a reported by BMI stated...
Gujarat will soon be able to share its strong pharmaceutical and healthcare ecosystem with the world through an international delegation from 41 countries on June 18, 2025. The visit is part of the 2nd...
.jpeg)
The alarming surge in fake medicines detected across multiple Indian states has stimulated drug regulators to push for immediate, forceful intervention to protect public health and restore trust in the country’s pharmaceutical ecosystem.
Eli Lilly's experimental obesity drug, eloralintide, has shown promising early-stage data supporting weight loss of an average of 11.5 percent after only 12 weeks, said an investor note from Cantor Fitzgerald...
 (1).png)
IOL Chemicals and Pharmaceuticals Limited has been honored with a Silver Medal by EcoVadis, achieving a creditable score of 71 and obtaining a position in the 89th percentile among companies evaluated worldwide.
 (1).png)
Bristol Myers Squibb has announced promising results of its fundamental tests of phase 3 Poatyk PSA-1 and PSA-2, evaluating Sotyktu (decravacitinib) in adults with active psoriatic arthritis (PSA).
An International Leader in Pharmaceutical Excipients Kolkata, 13 June 2025: The biggest manufacturer of microcrystalline cellulose (MCC) in India, Sigachi Industries Ltd., is steadily raising the bar for pharmaceutical excipients
Masimo, a global medical technology company developing and producing a wide array of industry-leading monitoring technologies, including innovative measurements, sensors, patient monitors, and automation and connectivity solutions, announced the find
.jpeg)
Shilpa Biocare, an integral Shilpa Medicare subsidiary, has signed a commercial supply contract across Europe with Orion Corporation for its recombinant human albumin, ahead of the Bio International Bio Convention in Boston.
 (1).png)
Merck, also known as MSD outside the U.S. and Canada, has initiated its Phase 3 clinical trial, MOBILIZE-1 (V181-005), to evaluate the safety, immunogenicity, and efficacy of its investigational dengue vaccine, V181.
, CDSCO.jpg)
